Compare Carvana Co (CVNA) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carvana Co vs Summit Therapeutics Inc — how do they compare? Carvana Co trades at $63.49 (market cap $69.55B), while Summit Therapeutics Inc trades at $17.54 (market cap $13.71B). The key difference: Carvana Co is far larger — about 5.1× Summit Therapeutics Inc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Carvana Co for 28 Days and Summit Therapeutics Inc for 16 Days on average.
| CVNA | SMMT | |
|---|---|---|
Market Cap | $69.55B | $13.71B |
Volume | 7,671,750 | 6,173,057 |
Sector | Consumer Cyclical | Health |
52-Week High | $95.69 | $26.38 |
52-Week Low | $56.27 | $12.43 |
Typical Hold Time | 28 Days | 16 Days |
Enterprise Value | $72.04B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carvana (CVNA) trades at $64.26, up 2.39% on the day, showing resilience amid a bearish technical signal. The company reported strong revenue growth to $20.32B in 2025 with net income of $1.41B, and has beaten EPS estimates for three consecutive quarters. Positive analyst sentiment is highlighted by a consensus price target of $84.07, though technical indicators suggest near-term caution with key support at $61.
Outlook remains positive due to robust earnings beats and expansion initiatives, but risks include high debt levels and competitive pressures. The stock offers growth potential if operational execution continues, yet investors should monitor cash flow sustainability and market volatility.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
